State Street
KYMR icon

State Street’s Kymera Therapeutics KYMR Stock Holding History

State Street’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$314M Buy
2,737,226
+347,459
+15% +$29.9M 0.01% 790
2026
Q1 		$199M Buy
2,389,767
+179,930
+8% +$14.2M 0.01% 934
2025
Q4 		$172M Buy
2,209,837
+190,383
+9% +$12.9M 0.01% 1030
2025
Q3 		$114M Buy
2,019,454
+465,023
+30% +$21M ﹤0.01% 1258
2025
Q2 		$67.8M Sell
1,554,431
-206,276
-12% -$7.1M ﹤0.01% 1522
2025
Q1 		$48.2M Buy
1,760,707
+71,918
+4% +$2.62M ﹤0.01% 1665
2024
Q4 		$67.9M Sell
1,688,789
-39,355
-2% -$1.78M ﹤0.01% 1559
2024
Q3 		$81.8M Sell
1,728,144
-182,547
-10% -$8.06M ﹤0.01% 1448
2024
Q2 		$57M Sell
1,910,691
-761,827
-29% -$26.4M ﹤0.01% 1606
2024
Q1 		$107M Buy
2,672,518
+778,239
+41% +$27.8M ﹤0.01% 1265
2023
Q4 		$48.2M Sell
1,894,279
-91,607
-5% -$1.64M ﹤0.01% 1721
2023
Q3 		$27.6M Sell
1,985,886
-634,423
-24% -$12.8M ﹤0.01% 1978
2023
Q2 		$60.2M Sell
2,620,309
-106,516
-4% -$3.05M ﹤0.01% 1550
2023
Q1 		$80.8M Sell
2,726,825
-119,396
-4% -$3.85M ﹤0.01% 1326
2022
Q4 		$71M Buy
2,846,221
+160,817
+6% +$4.29M ﹤0.01% 1404
2022
Q3 		$58.5M Sell
2,685,404
-829,034
-24% -$21.9M ﹤0.01% 1492
2022
Q2 		$69.2M Buy
3,514,438
+1,419,877
+68% +$33.2M ﹤0.01% 1419
2022
Q1 		$88.6M Buy
2,094,561
+452,799
+28% +$19.1M ﹤0.01% 1379
2021
Q4 		$104M Buy
1,641,762
+201,986
+14% +$11.8M ﹤0.01% 1267
2021
Q3 		$84.6M Buy
1,439,776
+103,130
+8% +$5.98M ﹤0.01% 1409
2021
Q2 		$64.8M Buy
1,336,646
+399,731
+43% +$17.4M ﹤0.01% 1656
2021
Q1 		$36.4M Buy
936,915
+776,370
+484% +$46.7M ﹤0.01% 1971
2020
Q4 		$9.95M Buy
+160,545
New +$7.83M ﹤0.01% 2631

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

State Street's KYMR Position: Q2 2026 in Review

State Street increased its Kymera Therapeutics (KYMR) stake by 15% in Q2 2026, buying an estimated $29.9M and bringing the position to 2,737,226 shares worth $314M. The position accounts for 0.01% of the portfolio, ranked #790.

State Street first reported a position in KYMR in Q4 2020 and has held it in 23 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • State Street held 2,737,226 shares of Kymera Therapeutics worth $314M as of Q2 2026.
  • State Street bought 347,459 Kymera Therapeutics shares in Q2 2026, an estimated $29.9M.
  • Kymera Therapeutics made up 0.01% of State Street's portfolio in Q2 2026, its #790 holding.
  • State Street first reported a position in Kymera Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.